TWI828593B - 醫藥組合物 - Google Patents

醫藥組合物 Download PDF

Info

Publication number
TWI828593B
TWI828593B TW112120572A TW112120572A TWI828593B TW I828593 B TWI828593 B TW I828593B TW 112120572 A TW112120572 A TW 112120572A TW 112120572 A TW112120572 A TW 112120572A TW I828593 B TWI828593 B TW I828593B
Authority
TW
Taiwan
Prior art keywords
obinutuzumab
patients
cycle
sdi
hour
Prior art date
Application number
TW112120572A
Other languages
English (en)
Chinese (zh)
Other versions
TW202342099A (zh
Inventor
麥可 溫格
梅爾達德 孟巴薛
錦瑜 林
Original Assignee
瑞士商赫孚孟拉羅股份公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64362606&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI828593(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 瑞士商赫孚孟拉羅股份公司 filed Critical 瑞士商赫孚孟拉羅股份公司
Publication of TW202342099A publication Critical patent/TW202342099A/zh
Application granted granted Critical
Publication of TWI828593B publication Critical patent/TWI828593B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW112120572A 2017-10-19 2018-10-19 醫藥組合物 TWI828593B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762574297P 2017-10-19 2017-10-19
US62/574,297 2017-10-19

Publications (2)

Publication Number Publication Date
TW202342099A TW202342099A (zh) 2023-11-01
TWI828593B true TWI828593B (zh) 2024-01-01

Family

ID=64362606

Family Applications (2)

Application Number Title Priority Date Filing Date
TW112120572A TWI828593B (zh) 2017-10-19 2018-10-19 醫藥組合物
TW107137033A TWI805630B (zh) 2017-10-19 2018-10-19 醫藥組合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW107137033A TWI805630B (zh) 2017-10-19 2018-10-19 醫藥組合物

Country Status (14)

Country Link
US (2) US12129304B2 (enExample)
EP (2) EP3697818B1 (enExample)
JP (2) JP6860652B2 (enExample)
KR (2) KR102766089B1 (enExample)
CN (2) CN120983618A (enExample)
AU (2) AU2018303836B2 (enExample)
BR (1) BR112020007731A2 (enExample)
CA (1) CA3079374A1 (enExample)
ES (1) ES3005784T3 (enExample)
IL (2) IL321935A (enExample)
MX (2) MX2020003418A (enExample)
PL (1) PL3697818T3 (enExample)
TW (2) TWI828593B (enExample)
WO (1) WO2019017499A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020003418A (es) * 2017-10-19 2020-07-20 Hoffmann La Roche Tratamiento de linfoma de células b positivo a cd20 con obinutuzumab.
US20240050562A1 (en) * 2019-10-04 2024-02-15 Chugai Seiyaku Kabushiki Kaisha Inhibitor of cell proliferation in obinutuzumab resistant cd20-positive cancer, and medicinal composition, medicine, production, method for inhibiting cell proliferation, therapeutic method, type ii anti-cd20 antibody, compounds, combination of same, enhancer and inducer, each relating thereto
JPWO2023042679A1 (enExample) 2021-09-17 2023-03-23

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016024228A1 (en) * 2014-08-11 2016-02-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor and/or a pd-l1 inhibitor
CN108395482A (zh) * 2017-02-08 2018-08-14 西比曼生物科技（上海）有限公司 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME01775B (me) 2003-11-05 2011-02-28 Glycart Biotechnology Ag Cd20 antitijela sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom
NZ585516A (en) 2007-12-21 2012-07-27 Hoffmann La Roche Anti-cd20 antibody formulation
US11149091B2 (en) * 2015-12-09 2021-10-19 Cedars-Sinai Medical Center Methods for treating nephrotic syndrome
JP6881583B2 (ja) 2017-07-21 2021-06-02 横浜ゴム株式会社 空気入りタイヤ
MX2020003418A (es) * 2017-10-19 2020-07-20 Hoffmann La Roche Tratamiento de linfoma de células b positivo a cd20 con obinutuzumab.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016024228A1 (en) * 2014-08-11 2016-02-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor and/or a pd-l1 inhibitor
CN108395482A (zh) * 2017-02-08 2018-08-14 西比曼生物科技（上海）有限公司 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
期刊 Kensei Tobinai A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies Adv Ther 34 2017 324-356 *

Also Published As

Publication number Publication date
IL321935A (en) 2025-09-01
US20200299398A1 (en) 2020-09-24
AU2018303836B2 (en) 2025-04-17
US12129304B2 (en) 2024-10-29
IL273909B2 (en) 2025-12-01
JP6860652B2 (ja) 2021-04-21
MX2024009217A (es) 2024-11-08
AU2018303836A1 (en) 2020-05-14
KR20240157135A (ko) 2024-10-31
BR112020007731A2 (pt) 2020-10-20
JP2019528282A (ja) 2019-10-10
PL3697818T3 (pl) 2025-03-24
EP3697818B1 (en) 2024-11-27
AU2025205481A1 (en) 2025-08-07
US20250026847A1 (en) 2025-01-23
TW202342099A (zh) 2023-11-01
TW201922284A (zh) 2019-06-16
IL273909B1 (en) 2025-08-01
WO2019017499A2 (en) 2019-01-24
EP4520347A3 (en) 2025-06-04
MX2020003418A (es) 2020-07-20
IL273909A (en) 2020-05-31
CA3079374A1 (en) 2019-01-24
JP2021152002A (ja) 2021-09-30
EP3697818A2 (en) 2020-08-26
WO2019017499A3 (en) 2019-02-21
CN120983618A (zh) 2025-11-21
TWI805630B (zh) 2023-06-21
CN111212854A (zh) 2020-05-29
KR102766089B1 (ko) 2025-02-13
ES3005784T3 (en) 2025-03-17
JP7370357B2 (ja) 2023-10-27
EP4520347A2 (en) 2025-03-12
KR20200067196A (ko) 2020-06-11

Similar Documents

Publication Publication Date Title
US20250026847A1 (en) Treatment of cd20-positive b-cell lymphoma with obinutuzumab
AU2016250388B2 (en) Treatment for rheumatoid arthritis
JP2024167278A (ja) Ｉｌ－７タンパク質と免疫チェックポイント阻害剤の組み合わせで腫瘍を治療する方法
JP2025156294A (ja) 皮下投与のための抗ｃｄ３８抗体の製剤
TW202131948A (zh) 用於治療白血病或淋巴瘤之抗cd19療法與來那度胺(lenalidomide)的組合
EP4041394A1 (en) Use of high-affinity, ligand-blocking, humanized anti-t-cell immunoglobulin domain and mucin domain-3 (tim-3) igg4 antibody for the treatment of myelofibrosis
US20230014026A1 (en) Anti-Tumor Combination Therapy comprising Anti-CD19 Antibody and Polypeptides Blocking the SIRPalpha-CD47 Innate Immune Checkpoint
Nowak et al. The position of monoclonal antibodies and small molecules in the treatment of thyroid orbitopathy
CN117769435A (zh) 通过施用抗cd127剂治疗cd127阳性癌症的方法
HK40031517A (en) Treatment of cd20-positive b-cell lymphoma with obituzumab
US20250099542A1 (en) Method of treating a tumor with a combination of il-7 protein and vegf antagonist
RU2817047C2 (ru) Новый подход к лечению рака с применением иммуномодуляции
WO2023114967A1 (en) Encapsulated cells expressing il-12 and uses thereof
US20220339174A1 (en) Method for the treatment of chronic fatigue syndrome using an inhibitory or cytotoxic agent against plasma cells
CA3235772A1 (en) Encapsulated cells expressing il-2 and uses thereof